Format

Send to

Choose Destination
J Ultrasound Med. 2019 Jun 24. doi: 10.1002/jum.15072. [Epub ahead of print]

Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis.

Author information

1
Department of Radiology, Keck School of Medicine, California, Los Angeles, USA.
2
Norris Medical Library, Keck School of Medicine, California, Los Angeles, USA.

Abstract

A systematic search was conducted to categorize targeted ultrasound contrast agents (UCAs) used in cancer-related angiogenesis detection. We identified 15 unique contrast agents from 2008 to March 2018. Most primary research articles studied UCAs targeted to vascular endothelial growth factor receptor or αv β3 -integrin. Breast cancer and colon cancer are the most common neoplastic processes in which these agents were studied. BR55 (Bracco Research SA, Geneva, Switzerland), a vascular endothelial growth factor receptor-targeting UCA, is the first targeted UCA that has completed phase 0 trials. Our review identifies a gap in the literature regarding the application of targeted UCAs in cancer models beyond breast and colon cancers and identifies other promising UCAs.

KEYWORDS:

angiogenesis; microbubbles; targeted contrast-enhanced ultrasound

PMID:
31237009
DOI:
10.1002/jum.15072

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center